Also, given that TME influences and determines tumor growth, treatment responsiveness, and patient prognosis18,19, this study explores an immune-related gene (PTPRC) in TME that has good predictive power for both prognosis and response to immunotherapy in melanoma patients through a comprehensive bioinformatics analysis. This evidence concerns the gene PTPRC and neoplasm.